MetaCap

Lineage Cell Therapeutics Inc. (LCTX)

NYSE: LCTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.7719-0.0481 (-5.87%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

LCTX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$195.26M
EPS (TTM)
-$0.09
Ex-dividend date
Dec 15, 2003
52-week range
0.77 – 1.99
Day range
0.77 – 0.8383
Volume / Avg
2.04M / 1.64M
Beta
—

52-week range

$0.77$1.99

LCTX stock today

On Nov 20, LCTX ended the session at $0.7719, shedding $0.0481 (5.87%), versus the S&P 500's 3.70% decline. Shares are 61.2% below their 52-week high of $1.99, set on Feb 26, 2026 and 0.2% above the 52-week low of $0.77, near the bottom of the past year's range. LCTX is down 53.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 55.6%.

Lineage Cell Therapeutics has posted a net loss over the last twelve months (EPS of -$0.09), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Lineage Cell Therapeutics

Company profile

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Brian M. Culley M.A., M.B.A.
Headquarters
Carlsbad, CA
Employees
72

Financial highlights

Full financials

In fiscal 2025, Lineage Cell Therapeutics generated $14.6 million in revenue, up 53.2% from fiscal 2024, its 2nd consecutive year of revenue growth. Lineage Cell Therapeutics reported a net loss of $63.5 million, compared with a loss of $18.6 million a year earlier. Operating margin was -251.6%.

Lineage Cell Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$14.56M$9.50M$8.95M$14.70M$4.34M
Growth+53.24%+6.19%-39.16%+238.70%+137.73%
Net income$-63.53M$-18.61M$-21.49M$-26.27M$-43.02M
EPS (diluted)$-0.28$-0.09$-0.12$-0.15$-0.26

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$5.50+612.53%

  • Strong buy 1
  • Buy 5
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $3.00High $9.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.13 vs $-0.02
Surprise
-550.00%

Dividends

Dividend history
Annual dividend
$0.00
Last payment
$0.0646
Ex-dividend date
Dec 15, 2003

LCTX news

All LCTX news

Lineage Cell Therapeutics peers

Health Care sector
LCTX peer companies
CompanyPrice% ChgMarket capCompare
CABACabaletta Bio Inc.0.9361-7.32%$201.94Mvs LCTX
ARTVArtiva Biotherapeutics Inc.3.78-1.31%$186.85Mvs LCTX
IKTInhibikase Therapeutics Inc.1.32+1.54%$185.16Mvs LCTX
IPSCCentury Therapeutics Inc.1.17-11.74%$211.56Mvs LCTX
CGENCompugen Ltd.1.84-2.13%$174.29Mvs LCTX
ALLOAllogene Therapeutics Inc.0.6277-5.88%$217.48Mvs LCTX
SCTXScribe Therapeutics Inc.12.07-8.70%$228.58Mvs LCTX
PALIPalisade Bio Inc.0.8399-9.24%$150.74Mvs LCTX

Indexes, lists and sector

Lineage Cell Therapeutics stock FAQ

What is Lineage Cell Therapeutics's stock price today?

LCTX last traded at $0.7719 as of Nov 20, 4:00 PM EST, down 5.87% on the day. Prices are delayed at least 15 minutes.

Does Lineage Cell Therapeutics pay a dividend?

Yes. Lineage Cell Therapeutics pays $0.00 per share annually. The most recent dividend of $0.0646 had an ex-dividend date of Dec 15, 2003.

Who is Lineage Cell Therapeutics's CEO?

Mr. Brian M. Culley M.A., M.B.A. is the chief executive officer of Lineage Cell Therapeutics Inc., which has about 72 employees.

Has LCTX ever split its stock?

Yes. The most recent LCTX stock split was a 3-for-1 split on Oct 31, 1997.

What is the LCTX 52-week high?

The 52-week high for LCTX is $1.99 and the 52-week low is $0.77. The stock is currently 61.2% below its high.

Compare LCTX